Keyphrases
Valproic Acid
100%
Aldehyde Dehydrogenase 2 (ALDH2)
100%
Triple-negative Breast Cancer Cells
100%
Cisplatin Treatment
100%
Metabolic Aberration
100%
Cisplatin
50%
MDA-MB-231 Cells
50%
Triple-negative Breast Cancer
37%
MDA-MB-436
37%
Disulfiram
25%
Extracellular Acidification
25%
Overexpression
12%
Glycolysis
12%
Glucose Metabolism
12%
Drug Resistance
12%
Western Blot
12%
Breast Cancer Patients
12%
Therapeutic Efficacy
12%
Metabolomics
12%
Cell Resistance
12%
Cell Cycle Distribution
12%
Histone Deacetylase Inhibitor (HDACi)
12%
Cytotoxic Effect
12%
Oxygen Consumption Rate
12%
Drug Combination
12%
Dehydrogenase Enzyme
12%
Oxidative Metabolism
12%
MDA-MB-231 Cancer Cells
12%
Cisplatin Resistance
12%
Real-time PCR Analysis
12%
Resistant Lines
12%
Glycolytic Metabolism
12%
Stress Testing
12%
Acid Addition
12%
Cisplatin-induced
12%
Hexose
12%
Sensitive Lines
12%
Organoid System
12%
Cisplatin Sensitivity
12%
Patient-derived Organoids
12%
Cell Cycle Alterations
12%
Breast Cancer Organoid
12%
Immunology and Microbiology
Cancer Cell
100%
Cell Line
100%
Cell Cycle
100%
Organoid
100%
Breast Cancer Cell Line
50%
Glucose Metabolism
50%
Real Time Polymerase Chain Reaction
50%
Cytotoxicity
50%
Oxygen Consumption
50%
Drug Resistance
50%
Western Blot
50%
Metabolome
50%
Aerobic Metabolism
50%
Neuroscience
Aldehyde Dehydrogenase
100%
Valproic Acid
100%
Cisplatin
100%
Cell Line
33%
Metabolic Pathway
22%
Cell Cycle
22%
Disulfiram
22%
Cytotoxicity
11%
Real-Time Polymerase Chain Reaction
11%
Histone Deacetylase Inhibitor
11%
Combination Drug
11%
Drug Resistance
11%
Metabolome
11%
Western Blotting
11%
Hexose
11%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Cisplatin
100%
Aldehyde Dehydrogenase
100%
Cell Cycle
22%
Disulfiram
22%
Real-Time Polymerase Chain Reaction
11%
Oxidoreductase
11%
Cytotoxicity
11%
Glucose Metabolism
11%
Drug Resistance
11%
Isoform
11%
Oxygen Consumption
11%
Histone Deacetylase
11%
Metabolome
11%
Aerobic Metabolism
11%
ALDH1A1
11%
Western Blotting
11%
Hexose
11%